Literature DB >> 27104887

Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.

Melissa A Linden1,2, Ryan D Sheldon1,2, Grace M Meers1,3, Laura C Ortinau2, E Matthew Morris4, Frank W Booth5,6,7, Jill A Kanaley2, Victoria J Vieira-Potter2, James R Sowers1,8, Jamal A Ibdah1,3,6, John P Thyfault4,9, M Harold Laughlin5, R Scott Rector10,11,12.   

Abstract

KEY POINTS: Physiologically relevant rodent models of non-alcoholic steatohepatitis (NASH) that resemble the human condition are limited. Exercise training and energy restriction are first-line recommendations for the treatment of NASH. Hyperphagic Otsuka Long-Evans Tokushima fatty rats fed a western diet high in fat, sucrose and cholesterol for 24 weeks developed a severe NASH with fibrosis phenotype. Moderate intensity exercise training and modest energy restriction provided some improvement in the histological features of NASH that coincided with alterations in markers of hepatic stellate cell activation and extracellular matrix remodelling. The present study highlights the importance of lifestyle modification, including exercise training and energy restriction, in the regulation of advanced liver disease. ABSTRACT: The incidence of non-alcoholic steatohepatitis (NASH) is rising but the efficacy of lifestyle modifications to improve NASH-related outcomes remain unclear. We hypothesized that a western diet (WD) would induce NASH in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat and that lifestyle modification would improve this condition. Eight-week-old Long-Evans Tokushima Otsuka (L) and OLETF (O) rats consumed a control diet (10% kcal fat, 3.5% sucrose) or a WD (45% kcal fat, 17% sucrose, 1% cholesterol) for 24 weeks. At 20 weeks of age, additional WD-fed OLETFs were randomized to sedentary (O-SED), food restriction (O-FR; ∼25% kcal reduction vs. O-SED) or exercise training (O-EX; treadmill running 20 m min(-1) with a 15% incline, 60 min day(-1) , 5 days week(-1) ) conditions for 12 weeks. WD induced a NASH phenotype in OLETFs characterized by hepatic fibrosis (collagen 1α1 mRNA and hydroxyproline content), as well as elevated inflammation and non-alcoholic fatty liver disease activity scores, and hepatic stellate cell activation (α-smooth muscle actin) compared to Long-Evans Tokushima Otsuka rats. FR and EX modestly improved NASH-related fibrosis markers (FR: hydroxyproline content, P < 0.01; EX: collagen 1α1 mRNA, P < 0.05; both: fibrosis score, P < 0.01) and inflammation (both: inflammation score; FR: interleukin-1β and tumor necrosis factor α) vs. O-SED. FR reduced hepatic stellate cell activation markers (transforming growth factor-β protein and α-smooth muscle actin mRNA), whereas EX increased the hepatic stellate cell senescence marker CCN1 (P < 0.01 vs. O-SED). Additionally, both FR and EX normalized extracellular matrix remodelling markers to levels similar to L-WD (P > 0.05). Although neither EX nor FR led to complete resolution of the WD-induced NASH phenotype, both independently benefitted liver fibrosis via altered hepatic stellate cell activation and extracellular matrix remodelling.
© 2016 The Authors. The Journal of Physiology © 2016 The Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27104887      PMCID: PMC5023692          DOI: 10.1113/JP272235

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  53 in total

Review 1.  Nonalcoholic fatty liver disease: an agenda for clinical research.

Authors:  Zobair M Younossi; Anna Mae Diehl; Janus P Ong
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

Review 2.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

Authors:  Christian Thoma; Christopher P Day; Michael I Trenell
Journal:  J Hepatol       Date:  2011-07-01       Impact factor: 25.083

3.  Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model.

Authors:  R Scott Rector; Grace M Uptergrove; E Matthew Morris; Sarah J Borengasser; M Harold Laughlin; Frank W Booth; John P Thyfault; Jamal A Ibdah
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-02-24       Impact factor: 4.052

4.  Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease.

Authors:  Maria Cristina Elias; Edison Roberto Parise; Luciana de Carvalho; Denis Szejnfeld; João Prola Netto
Journal:  Nutrition       Date:  2009-12-22       Impact factor: 4.008

5.  Changes in skeletal muscle mitochondria in response to the development of type 2 diabetes or prevention by daily wheel running in hyperphagic OLETF rats.

Authors:  R Scott Rector; Grace M Uptergrove; Sarah J Borengasser; Catherine R Mikus; E Matthew Morris; Scott P Naples; Matthew J Laye; M Harold Laughlin; Frank W Booth; Jamal A Ibdah; John P Thyfault
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-03-16       Impact factor: 4.310

6.  The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling.

Authors:  Erawan Borkham-Kamphorst; Christian Schaffrath; Eddy Van de Leur; Ute Haas; Lidia Tihaa; Steffen K Meurer; Yulia A Nevzorova; Christian Liedtke; Ralf Weiskirchen
Journal:  Biochim Biophys Acta       Date:  2014-01-31

7.  MMP-9 activity is increased by adiponectin in primary human hepatocytes but even negatively correlates with serum adiponectin in a rodent model of non-alcoholic steatohepatitis.

Authors:  Josef Wanninger; Roland Walter; Sabrina Bauer; Kristina Eisinger; Andreas Schäffler; Christoph Dorn; Thomas S Weiss; Claus Hellerbrand; Christa Buechler
Journal:  Exp Mol Pathol       Date:  2011-07-21       Impact factor: 3.362

8.  Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats.

Authors:  Melissa A Linden; Justin A Fletcher; E Matthew Morris; Grace M Meers; Monica L Kearney; Jacqueline M Crissey; M Harold Laughlin; Frank W Booth; James R Sowers; Jamal A Ibdah; John P Thyfault; R Scott Rector
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-12-10       Impact factor: 4.310

Review 9.  Is exercise an effective treatment for NASH? Knowns and unknowns.

Authors:  Stephen Caldwell; Mariana Lazo
Journal:  Ann Hepatol       Date:  2009       Impact factor: 2.400

10.  Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis.

Authors:  Ali Canbay; Hajime Higuchi; Steven F Bronk; Makiko Taniai; Tom J Sebo; Gregory J Gores
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

View more
  12 in total

1.  Estrogen receptor-α signaling maintains immunometabolic function in males and is obligatory for exercise-induced amelioration of nonalcoholic fatty liver.

Authors:  Nathan C Winn; Thomas J Jurrissen; Zachary I Grunewald; Rory P Cunningham; Makenzie L Woodford; Jill A Kanaley; Dennis B Lubahn; Camila Manrique-Acevedo; R Scott Rector; Victoria J Vieira-Potter; Jaume Padilla
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-12-04       Impact factor: 4.310

2.  Aerobic capacity mediates susceptibility for the transition from steatosis to steatohepatitis.

Authors:  E Matthew Morris; Colin S McCoin; Julie A Allen; Michelle L Gastecki; Lauren G Koch; Steven L Britton; Justin A Fletcher; Xiarong Fu; Wen-Xing Ding; Shawn C Burgess; R Scott Rector; John P Thyfault
Journal:  J Physiol       Date:  2017-06-27       Impact factor: 5.182

3.  Sex modulates hepatic mitochondrial adaptations to high-fat diet and physical activity.

Authors:  Colin S McCoin; Alex Von Schulze; Julie Allen; Kelly N Z Fuller; Qing Xia; Devin C Koestler; Claire J Houchen; Adrianna Maurer; Gerald W Dorn; Kartik Shankar; E Matthew Morris; John P Thyfault
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-04-30       Impact factor: 4.310

Review 4.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

5.  Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus.

Authors:  Ryuta Shigefuku; Hideaki Takahashi; Hiroyasu Nakano; Tsunamasa Watanabe; Kotaro Matsunaga; Nobuyuki Matsumoto; Masaki Kato; Ryo Morita; Yousuke Michikawa; Tomohiro Tamura; Tetsuya Hiraishi; Nobuhiro Hattori; Yohei Noguchi; Kazunari Nakahara; Hiroki Ikeda; Toshiya Ishii; Chiaki Okuse; Shigeru Sase; Fumio Itoh; Michihiro Suzuki
Journal:  Int J Mol Sci       Date:  2016-09-14       Impact factor: 5.923

6.  Endurance training lowers ribosome density despite increasing ribosome biogenesis markers in rodent skeletal muscle.

Authors:  Matthew A Romero; C Brooks Mobley; Melissa A Linden; Grace Margaret-Eleanor Meers; Jeffrey S Martin; Kaelin C Young; R Scott Rector; Michael D Roberts
Journal:  BMC Res Notes       Date:  2017-08-11

Review 7.  Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism.

Authors:  Kyle S McCommis; Brian N Finck
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-10-10

Review 8.  Impacts of exercise intervention on various diseases in rats.

Authors:  Ruwen Wang; Haili Tian; Dandan Guo; Qianqian Tian; Ting Yao; Xingxing Kong
Journal:  J Sport Health Sci       Date:  2019-10-28       Impact factor: 7.179

9.  Genistein and exercise treatment reduced NASH related HDAC3, IL-13 and MMP-12 expressions in ovariectomized rats fed with high fat high fructose diet.

Authors:  Namthip Witayavanitkul; Duangporn Werawatganon; Maneerat Chayanupatkul; Naruemon Klaikeaw; Prasong Siriviriyakul
Journal:  J Tradit Complement Med       Date:  2021-05-03

10.  Genistein and exercise modulated lipid peroxidation and improved steatohepatitis in ovariectomized rats.

Authors:  Namthip Witayavanitkul; Duangporn Werawatganon; Maneerat Chayanupatkul; Naruemon Klaikeaw; Sompol Sanguanrungsirikul; Prasong Siriviriyakul
Journal:  BMC Complement Med Ther       Date:  2020-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.